Make scientific figures in minutes
Create publication-quality figures with pre-made icons and templates, all from BioRender's web-based software
Use Icons In The App
Try a synonym, or sign up to request an icon from the app.
Target identification (DNA, symbol)
[{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0507/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0507/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0508/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0508/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0509/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0509/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050a/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050a/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050b/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050b/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050c/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050c/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050d/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050d/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050e/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050e/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e050f/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e050f/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0510/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0510/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0511/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0511/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0512/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0512/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0513/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0513/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0514/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0514/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0515/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0515/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0516/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0516/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0517/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0517/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0518/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0518/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0519/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0519/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051a/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051a/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051b/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051b/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051c/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051c/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051d/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051d/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051e/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051e/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e051f/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e051f/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0520/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0520/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0521/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0521/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0522/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0522/67f56a6432668bc7e42e04e4.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/67f56a8f32668bc7e42e0523/67f56a6432668bc7e42e04e4.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/67f56a8f32668bc7e42e0523/67f56a6432668bc7e42e04e4.png"}]
Use this icon in BioRender along with 1000s of others to make your next science figure in minutes
.png)
SIGN UP FREEKeywords
target identification,drug discovery,biomedical research,molecular biology,genomics,proteomics,genetic target discovery,DNA targeting,nucleic acid research,gene editing,CRISPR,genetic engineering,DNA biomarker identification,precision medicine,genomic screening,gene therapy,transcriptomics,functional genomics,chemical biology,rna target identification,dna target identification,protein target identification,therapeutic target discovery,target validation,genetic screening,gene expression analysis,bioinformatics,next-generation sequencing,high-throughput screening,mass spectrometry,affinity-based screening,target engagement,binding assays,cell-based assays,biomarker discovery,cancer research,infectious disease research,neuroscience research,pharmacology,precision medicine,rna-seq,chip-seq,crisper screening,siRNA screening,antisense oligonucleotides,molecular target profiling,target-ligand interaction,mechanism of action studies,computational biology,systems biology,drug target mapping,gene knockout studies,protein-dna interactions,protein-rna interactions,small molecule screening,target deconvolution,therapeutic development,translational research,structure-based drug design,cell signaling pathways,disease pathway analysis,molecular diagnostics,biological target identification,rna-binding proteins,transcription factor profiling,target identification platforms,target-based screening,target characterization,genetic perturbation,target annotation,multi-omics integration,schematic,symbol,symbolic,sign,icon,iconography,mark,signify,simple,content-refinement-AI-expansion,target identification,drug discovery,biomedical research
Image types
BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More
Related Categories
Join 1,500,000 other scientists on BioRender
Sign up for your free account and start creating scientific figures faster today
FAQs
What is BioRender?
Can I use this icon in a BioRender figure or scientific illustration?
